AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2415098
Drug: Topical framycitin/gramicidin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical framycitin/gramicidin (Sofradex)
Trial: 12030960
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg for 7 days)
Trial: 9933263
Drug: High titers
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titers of antibodies to Chlamydia pneumoniae (IgA or IgG)
Trial: 2276774
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (68 babies for prophylactic study, 34 babies for treatment study)
Trial: 361348
Drug: Carbenoxolone/alginate antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone/alginate antacid combination
Trial: 361348
Drug: Alginate antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate antacid compound used alone
Trial: 31359143
Drug: TNFi treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFi treatment
Trial: 31484710
Drug: ocrelizumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ocrelizumab (600 mg)
Trial: 21924882
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d EPA + DHA
Trial: 18458964
Drug: Low-energy laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy laser (LEL) treatment as preventive treatment
Trial: 18458964
Drug: Low-energy laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy laser (LEL) treatment as therapeutic intervention
Trial: 11085323
Drug: MDMA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA treatment
Trial: 6353434
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg prazepam (divided dosage)
Trial: 6353434
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg prazepam (single night time dosage)
Trial: 6353434
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg diazepam (divided dosage)
Trial: 24714489
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) infusion
Trial: 24714489
Drug: NAC in
RxNorm normalized name: diclofenac Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC in combination with NaHCO3
Trial: 24714489
Drug: Hydration with
RxNorm normalized name: Gold Bond Healing Hydration with Aloe Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration with sodium chloride infusion alone
Trial: 24714489
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride infusion alone
Trial: 21182457
Drug: V-5 Immunitor
RxNorm normalized name: V-5 Immunitor
DrugBank: Tubimod (DB17745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V-5 Immunitor (V5) immunotherapy pill
Trial: 19018197
Drug: Ultrasonic mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic mist therapy
Trial: 19018197
Drug: Sham device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham device or alternative treatments
Trial: 16763747
Drug: LKFibre diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LKFibre diet (17-30 g/day fiber)
Trial: 14670885
Drug: Borage oil
RxNorm normalized name: Borage oil
DrugBank: Borage oil (DB11238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Borage oil (920 mg gamma linolenic acid) - adults received four capsules twice daily, children received two capsules twice daily for 12 weeks.
Trial: 14670885
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - control group receiving placebo treatment for 12 weeks.
Trial: 30012185
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of monomeric and oligomeric flavanols (MOF) daily for 3 months
Trial: 20129679
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac 1mg/kg per-rectal post-induction of anaesthesia
Trial: 14619641
Drug: Alendronate, 10
RxNorm normalized name: Alendronate, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 10 mg, daily for 6 months
Trial: 1760826
Drug: Isosorbide-5-mononitrate (ISMN),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (ISMN), orally 20 mg 2-3 times daily
Trial: 7051813
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin therapy
Trial: 24211154
Drug: Static progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Static progressive stretch device plus traditional therapy
Trial: 18756743
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy alone
Trial: 12078788
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (2 x 10(6) KIU = 280 mg)
Trial: 25740906
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract supplementation (0.56 g/d epigallocatechin gallate + 0.28-0.45 g/d caffeine)
Trial: 22830987
Drug: Jet injection
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet injection of rapid-acting insulin analogs
Trial: 31154419
Drug: Sequential co-enrolment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential co-enrolment in randomized trials
Trial: 31066303
Drug: 0.35 mg
RxNorm normalized name: nicotine 0.35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35 mg oral norethindrone with continuation of transdermal oestradiol patches (NET)
Trial: 31066303
Drug: Oestradiol withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol withdrawal by patch removal (E2WD)
Trial: 19230461
Drug: Phenylephrine 12
RxNorm normalized name: chlorcyclizine-phenylephrine 12.5 mg-5 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 12 mg
Trial: 3527811
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (MPSS), 2 to 3 g i.v. three hours apart within 12 hours of chest pain onset
Trial: 27344822
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling therapy and auricular acupuncture (observation group)
Trial: 27344822
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling therapy (control group)
Trial: 15676086
Drug: Control (normothermia,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normothermia, no hypothermia treatment)
Trial: 8714860
Drug: Standard zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard zinc therapy
Trial: 27749534
Drug: Cabergoline 0.5
RxNorm normalized name: cabergoline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.5 mg, once per week for 3 months
Trial: 8740091
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (T) of tamoxifen 30 mg
Trial: 8740091
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (R) of N-desmethyl-tamoxifen
Trial: 25149383
Drug: FGR group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGR group with treatment (animal experiment)
Trial: 25149383
Drug: FGR group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGR group without treatment (animal experiment)
Trial: 22968413
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of four probiotics and four fibres
Trial: 10853971
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg once daily
Trial: 10853971
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice daily
Trial: 24205802
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal blockade with 30 ml ropivacaine 7.5 mg/ml (n=36)
Trial: 21416785
Drug: Adjustable dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable dosing of budesonide/formoterol (Symbicort, 80/4.5 microg and 160/4.5 microg)
Trial: 15860863
Drug: Routine screening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine screening, evaluation, and treatment
Trial: 18727454
Drug: Thiocolchicoside 8
RxNorm normalized name: Etoricoxib 90 mg and thiocolchicoside 8 mg conventional release and prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiocolchicoside 8 mg twice daily (b.i.d.)
Trial: 15779223
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection using 2% lidocaine with 1:100,000 epinephrine
Trial: 15779223
Drug: Infiltration injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 0.02 g in 1 mL INFILTRATION INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration injection using 2% lidocaine with 1:100,000 epinephrine
Trial: 8646872
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 0.005% ointment, applied topically up to 100 gm/week, twice daily for up to four weeks
Trial: 6390802
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (Solu-Medrol) in addition to antibiotics and early surgical intervention
Trial: 25113885
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine (2 mg/kg) and glucosamine (25 mg/kg) for 8 weeks
Trial: 25113885
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine alone for 8 weeks
Trial: 12888783
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose ketamine
Trial: 12888783
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose ketamine
Trial: 2296626
Drug: Caffeine 250
RxNorm normalized name: caffeine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 250 mg
Trial: 1444724
Drug: Caffeine 500
RxNorm normalized name: aspirin-caffeine 500 mg-32 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 500 mg
Trial: 12648865
Drug: HRT (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (a combination of oral conjugated estrogen 0.625 mg and medroxyprogesterone acetate 5 mg daily)
Trial: 12648865
Drug: HRT +
RxNorm normalized name: Hormone Replacement Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT + MFP (HRT combined with oral monofluorophosphate 25 mg per day)
Trial: 12648865
Drug: MFP (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP (oral monofluorophosphate 25 mg per day)
Trial: 8985298
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg daily
Trial: 8752839
Drug: Topical phosphodiesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical phosphodiesterase inhibitor (CP80,633)
Trial: 1872724
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of sublingual nifedipine
Trial: 11295959
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil hydrochloride (240 mg/d)
Trial: 1826912
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg/d)
Trial: 3552106
Drug: Gentamicin 80
RxNorm normalized name: gentamicin 80 mg/50 mL-0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 80 mg IV
Trial: 30507887
Drug: Osteotome site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteotome site preparation (Control)
Trial: 12139210
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (2 g metamizole)
Trial: 10460199
Drug: Diurnal oral
RxNorm normalized name: Diuresal Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diurnal oral fat load test (OFLT) at 0700 h
Trial: 2215101
Drug: 1.8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg/kg propofol
Trial: 2215101
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg propofol
Trial: 25881872
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of piperacillin/tazobactam (11.25g/day on Day 1 followed by 9g/day)
Trial: 25881872
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus (IB) administration of piperacillin/tazobactam (11.25g/day on Day 1 followed by 9g/day)
Trial: 25881872
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of piperacillin
Trial: 17719703
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral feeding
Trial: 15113366
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy with rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. (low-dose therapy)
Trial: 15113366
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy with rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 500 mg b.d. (high-dose therapy)
Trial: 1748229
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (150 mg/day)
Trial: 20649626
Drug: Fenofibrate (145
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (145 mg/day)
Trial: 11677198
Drug: Ethinylestradiol (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol (0.01 mg) plus norethisterone (2 mg) (1 tablet/d)
Trial: 11677198
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet/d)
Trial: 9126796
Drug: Diuretics (spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (spironolactone 100-400 mg/day and furosemide 80-320 mg/day)
Trial: 9126796
Drug: Large-volume paracentesis
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-volume paracentesis plus intravenous albumin (6-8 g/l ascites removed)
Trial: 1392697
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg i.v. infusion of alendronate over 2 hours (group A, n = 10)
Trial: 1392697
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg i.v. infusion of alendronate over 24 hours (group B, n = 10)
Trial: 1392697
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (A and B)
Trial: 3908126
Drug: Acebutolol 400-600
RxNorm normalized name: acebutolol 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 400-600 mg/day
Trial: 3908126
Drug: Hydrochlorothiazide 25-50
RxNorm normalized name: captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25-50 mg/day
Trial: 21630032
Drug: bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (200 mg twice daily)
Trial: 21857087
Drug: ω‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 fatty acids (1 g twice daily)
Trial: 19215552
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) on day 1 and vaginal misoprostol (800 microg) on day 3
Trial: 17126406
Drug: Creative discipline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creative discipline controls (CC)
Trial: 12582815
Drug: 4-h mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-h mixed AA co-infusion (120 g mixed AA: 26.4 g l-lysine + l-arginine)
Trial: 12582815
Drug: 10-h mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-h mixed AA co-infusion (240 g mixed AA: 52.8 g l-lysine + l-arginine)
Trial: 12582815
Drug: 4-h Lys-Arg
RxNorm normalized name: Arg
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-h Lys-Arg co-infusion (25 g each)
Trial: 12005465
Drug: No infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No infusion
Trial: 12582815
Drug: 4-h mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-h mixed AA co-infusion
Trial: 1833610
Drug: Oestradiol patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol patch applied for 3-5 days on 20 cm2 of skin
Trial: 6231043
Drug: 4% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lignocaine spray 2 ml
Trial: 6231043
Drug: Halothane (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halothane (0.5 or 1.5%) and thiopentone (4.5 or 10 mg kg‐1)
Trial: 6231043
Drug: Thiopentone (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (higher dose)
Trial: 27079247
Drug: Routinely used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routinely used chlorhexidine gluconate solutions
Trial: 24048369
Drug: Combined prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined prednisolone (20 mg/day) and LMW heparin (1 mg/kg/day) starting on the first day of ovarian stimulation and one day after oocyte retrieval, respectively.
Trial: 18705820
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day naloxone PR
Trial: 18705820
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day naloxone PR
Trial: 18705820
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day naloxone PR
Trial: 18705820
Drug: 2:1 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2:1 dose ratio of oxycodone to naloxone
Trial: 1499598
Drug: Moxonidine 0.2
RxNorm normalized name: moxonidine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.2 mg fasting
Trial: 6670341
Drug: Regular, non
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular, non medicamentous individual treatment in group A
Trial: 27484299
Drug: Long-stay group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-stay group (6 months inpatient + 6 monthly return visits)
Trial: 20681279
Drug: Wuzi Yanzong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuzi Yanzong Pill (WYP) for 3 months
Trial: 11781402
Drug: Valacyclovir (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (1 gram, three times daily for 24 weeks)
Trial: 8540716
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily) plus streptomycin (1 g/day, intramuscularly for 14 days)
Trial: 8540716
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily) plus rifampin (900 mg/day, single morning dose for 45 days)
Trial: 1771284
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin 2 micrograms/kg
Trial: 6167119
Drug: Tetracycline chloride
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline chloride 1 g/day for one week
Trial: 30932750
Drug: Montmorency cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency cherry (MC) supplement
Trial: 30932750
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) supplement
Trial: 31801326
Drug: Diabetes specific
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes specific nutrition supplement (DSNS) along with lifestyle intervention
Trial: 23630119
Drug: l-dopa/carbidopa (LC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-dopa/carbidopa (LC)
Trial: 23630119
Drug: l-dopa dose
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l-dopa dose